Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: Results of a randomized quality of life focused clinical trial

International Journal of Cancer

Volumn 113, Issue 4, 2005, Pages 632-639

  Olweny, Charles L M ^a,e   Borok, Margaret ^b   Gudza, Ivy ^b   Clinch, Jennifer ^a   Cheang, Mary ^c   Kiire, Clem F ^b   Levy, Lorraine ^b   Otim Oyet, David ^d   Nyamasve, Joseph ^d   Schipper, Harvey ^a  

^a WHO Collaborating Ctr Qual Life C   (Canada)

^b UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^c UNIVERSITY OF MANITOBA   (Canada)

^d WHO Regional Office for Africa   (Zimbabwe)

^e ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

AIDS associated Kaposi's sarcoma; Quality of life

Indexed keywords

BLEOMYCIN; COTRIMOXAZOLE; DACTINOMYCIN; ETOPOSIDE; ISONIAZID; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; ENVIRONMENT; EPIDEMIC; ERROR; EVALUATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; OUTCOMES RESEARCH; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STANDARD; VOMITING; ZIMBABWE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETOPOSIDE; FEMALE; HUMANS; MALE; PALLIATIVE CARE; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY; SARCOMA, KAPOSI; TREATMENT OUTCOME; ZIMBABWE;

EID: 19944386899     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20606     Document Type: Article

References (38)

1. Borok M, Gudza I, Kiire C, Levy L, Otim-Oyet D, Olweny C, Clinch J, Schipper H. Fulminant epidemic Kaposi's sarcoma (EKS): hallmark of AIDS in Zimbabwe. ASCO Proc 1996;15:304 (Abstract #849).
2. Antman K, Chang Y. Kaposi's sarcoma N Engl J Med 2000;342;1027-38.
3. Moore PS, Chang Y. Detection of herpes virus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 1995;332:1181-5.
4. Chang Y, Ziegler J, Wabinga H, Katongole-Mbidde E, Boshoff C, Schultz T, Whitby D, Maddalena D, Jaffe HW, Weiss RA. Kaposi's sarcoma-associated herpes virus and Kaposi's sarcoma in Africa. Arch Intern Med 1996;156:202-4.
5. Chokunonga E, Levy LM, Bassett MT, Borok M, Mauchaza B, Chirenje M, Parkin MD. AIDS and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS 1999;13:2583-8.
6. Chokunonga E, Levy LM, Bassett MT, Mauchaza B, Thomas D, Parkin DM. Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993-1995. Int J Cancer 2000;85:54-9.
7. Olweny CLM, Toya T, Katongole-Mbidde E, Lwanga S, Owor R, Kyalwazi SK, Vogel CL. Treatment of Kaposi's sarcoma by combination of actinomycin-D, vincristine and imidazole carboxamide (NSC 45388): results of a randomized clinical trial. Int J Cancer 1974;14:649-56.
8. Latif AS. The heterosexual transmission, clinical features and progression of infection with the Human Immunodeficiency Virus in Zimbabwe. MD Thesis, University of Zimbabwe, 1995.
9. Chachoua A, Krigel R, Lafleur R. Ostreicher R, Speer M, Lauberstein L, Wernz J, Rubensein P, Zang E, Friedman-Kien A. Prognostic factors and staging classification of patients with epidemic Kaposi's sarcoma. J Clin Oncol 1989;7:774-80.
10. Fitzpatrick PJ, Rider WD. Half body radiotherapy. Int J Radiat Onc Biol Phys 1989;56:335.
11. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: WHO, 1979.
12. Aaronson NK, Bullinger M, Ahmedzi S. A modular approach to quality of life assessment in cancer clinical trials. Rec Res Cancer Res 1988;11:231-49.
13. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy induced emesis. Qual Life Res 1992;1:331-40.
14. Morrow GR, Lindke J, Black P. Measurement of quality of life in patients: psychometric analysis of the Functional Living Index-Cancer (FLI-C). Qual Life Res 1992;1:287-96.
15. Ruckdeschell JC, Pianadosi S and the Lung Cancer Study Group. Quality of life in lung cancer surgical adjuvant trials. Chest 1994;106(Suppl):324-8.
16. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of patients: The Functional Living Index-Cancer: development and validation. J Clin Oncol 1984;2:472-83.
17. Clinch J, Olweny C, Schipper H, Borok M, Gudza I, Kiire C, Levy L, Otim-Oyet D. Cross-cultural validation of the Functional Living Index-Cancer (FLI-C): using epidemic Kaposi's sarcoma patients in Zimbabwe. ASCO Proc 1995;14:503 (Abstract #1649).
18. Schipper H, Clinch J, Goh C, Olweny C, Tan C, Chan M, Borok M, Gudza I. Cross-cultural experience using the FLI-C in Zimbabwe and Singapore. Qual Life Res 1995;4:482.
19. Goh CR, Lee KS, Tan TC, Wang TL, Tan CH, Wong J, Ang PT, Chan ME, Clinch J, Olweny CL, Schipper H. Measuring quality of life in different cultures: translation of the Functional Living Index for Cancer (FLI-C) into Chinese, Malay in Singapore. Ann Acad Med Singapore 1996;25:323-4.
20. Jordhoy MS, Fayers P, Loge JH, Ahlner-Elmquist M, Kaasa S. Quality of life in palliative cancer care: results from a cluster randomized trial. J Clin Onc 2001;19:3884-94.
21. Fauci A. The AIDS epidemic considerations for the 21st century. N Engl J Med 1999;341:1046-50.
22. Grulich A, Li Y, McDonald AM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001;15:629-33.
23. Taylor JF, Templeton AC, Vogel CL, Ziegler JL, Kyalwazi SK. Kaposi's sarcoma in Uganda: a clinicopathological study. Int J Cancer 1971;8:122-35.
24. Nasti G, Errante D, Santarossa S, Vaccher E, Tirelli U. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma. Drug Safety 1999;20:403-25.
25. Grunaug M, Bogner JR, Loch Q, Goebel FD. Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. Eur J Med Res 1998;3:13-9.
26. Coates A, Thomson D, McLeod ERM, Hersey P, Gill PG, Olver IN, Kefford R, Lowenthal R, Beadle G, Walpole E. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993;29A:1731-4.
27. Coates A, Gebski V, Signorini D, Murray R, McNeil D, Byrne M, Forbes JF. For the Australian New Zealand Breast Cancer Trials Group. Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. J Clin Onc 1992;10:1833-8.
28. Olweny CLM, Kaddu-Mukasa A, Atine I, Owor R, Magrath I, Ziegler JL. Childhood Kaposi's sarcoma: clinical features and therapy. Br J Cancer 1976;33:555-60.
29. Gill PS, Rarick M, McCutchan JA, Slater L, Parker B, Muchmore E, Bernstein-Singe M, Akil B, Espina BM, Krailo M, Levine A. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991;90:427-33.
30. Uthayakomar S, Bower M, Money-Kyrle J, Muyshondt C, Youle M, Hannon F, Phillips R, Gazzard BG, Boag F. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. AIDS 1996;10:515-9.
31. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, Hayden von Roenn J, Jacobs M, Kempin S, Silverbrg I, Gonzales G, Rarick MV, Myers AM, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14:2353-64.
32. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, DuMond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51.
33. Gill PS, Tulpole A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, Louie S, Gustafson NF, Brown MA, Orcutt C, Winograd B, Scadden DT. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999;17:1876-83.
34. Nasti G, Errente D, Talamini R, Rizzardini G, Fasan M, Landonio G, Zeroli C, Chichino G, Nigra E, Vancher E, Tirelli U. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. J Clin Oncol 2000;18:1550-7.
35. Gill J, Bourboulia D, Wilkinson J. Prospective study of the effects of and retroviral therapy on Kaposi's sarcoma-associated herpes virus infection in patients with and without Kaposi's sarcoma. J AIDS 2002;31:384-90.
36. Noy A, Gill P, Scadden D. Angiogenesis inhibitor IM862 is effective against AIDS-KS in a randomized, placebo controlled trail (Abstract). 6th International Conference in Malignancies in AIDS and Other Immunodeficiencies, 2002.
37. Coates TJ, Collins C. Preventing HIV infection. Sci Am 1998;279(1):96-7.
38. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Sherer W, Jacobson RL, Jimenez E, O'Neill E, et al. Reduction of maternal infant transmission of human immunodeficiency virus type 1 with zidovdine treatment. N Engl J Med 1994;331:1173-80.